Adoptive Cellular Transfer Immunotherapies for Cancer.
ACT(1)
cancer(5)
cell therapies(3)
immune cells(4)
immunotherapies(2)
Journal
Cancer treatment and research communications
ISSN: 2468-2942
Titre abrégé: Cancer Treat Res Commun
Pays: England
ID NLM: 101694651
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
03
2022
revised:
05
05
2022
accepted:
07
05
2022
pubmed:
10
6
2022
medline:
3
9
2022
entrez:
9
6
2022
Statut:
ppublish
Résumé
Patients with cancer require efficient treatment approaches as the mortality rate due to their disease is high. Conventional therapies, like chemotherapy and radiation, have severe side effects. Drug discovery is focusing on the development of alternative strategies that could have beneficial effects to the patients. Cellular therapies are potential therapeutics, and the generation of new products is growing fast. The concept involves the isolation of immune cells, ex vivo activation and reinfusion into the patient. The goal is to boost the immune cells to fight cancer cells. Different immune cells can be used, including dendritic cells, T cells, NK cells, macrophages and B lymphocytes. Some products have already gained FDA approval, while many more are currently in clinical trials. Research is focusing on the improvement of the function of the cells that may require genetic modification or combination with other therapies. Finally, it is crucial to develop novel technologies that could be used in monitoring of the immune profile of patients that have received a cellular therapy to assess the efficacy of the treatment.
Identifiants
pubmed: 35679756
pii: S2468-2942(22)00065-X
doi: 10.1016/j.ctarc.2022.100575
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100575Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.